1. Home
  2. PKBK vs OMER Comparison

PKBK vs OMER Comparison

Compare PKBK & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PKBK
  • OMER
  • Stock Information
  • Founded
  • PKBK 1999
  • OMER 1994
  • Country
  • PKBK United States
  • OMER United States
  • Employees
  • PKBK N/A
  • OMER 202
  • Industry
  • PKBK Major Banks
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • PKBK Finance
  • OMER Health Care
  • Exchange
  • PKBK Nasdaq
  • OMER Nasdaq
  • Market Cap
  • PKBK 256.4M
  • OMER 304.9M
  • IPO Year
  • PKBK N/A
  • OMER 2009
  • Fundamental
  • Price
  • PKBK $22.25
  • OMER $4.40
  • Analyst Decision
  • PKBK
  • OMER Strong Buy
  • Analyst Count
  • PKBK 0
  • OMER 5
  • Target Price
  • PKBK N/A
  • OMER $18.00
  • AVG Volume (30 Days)
  • PKBK 27.0K
  • OMER 1.4M
  • Earning Date
  • PKBK 10-17-2025
  • OMER 08-14-2025
  • Dividend Yield
  • PKBK 3.39%
  • OMER N/A
  • EPS Growth
  • PKBK 42.58
  • OMER N/A
  • EPS
  • PKBK 2.56
  • OMER N/A
  • Revenue
  • PKBK $66,879,999.00
  • OMER N/A
  • Revenue This Year
  • PKBK N/A
  • OMER N/A
  • Revenue Next Year
  • PKBK N/A
  • OMER $9,040.39
  • P/E Ratio
  • PKBK $8.29
  • OMER N/A
  • Revenue Growth
  • PKBK 3.52
  • OMER N/A
  • 52 Week Low
  • PKBK $16.94
  • OMER $2.95
  • 52 Week High
  • PKBK $24.29
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • PKBK 62.96
  • OMER 58.68
  • Support Level
  • PKBK $21.23
  • OMER $4.06
  • Resistance Level
  • PKBK $22.24
  • OMER $4.55
  • Average True Range (ATR)
  • PKBK 0.49
  • OMER 0.29
  • MACD
  • PKBK 0.05
  • OMER 0.03
  • Stochastic Oscillator
  • PKBK 98.67
  • OMER 84.04

About PKBK Parke Bancorp Inc.

Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: